百川智能转向医疗健康，计划2027年IPO

做的是什么生意

A Chinese AI healthcare company: self-developed healthcare large model Baichuan-M3 (open-sourced) and AI consultation product Baixiaoying (百小应), entering from scenarios such as pediatrics and oncology, providing serious healthcare decision support to patients, and later commercializing through service packages or partnerships with pharmaceutical and medical device companies.

启动资金：In July 2024, it completed a Series A funding round of RMB 5 billion (during a capital winter); as of January 2026, its book cash reserves were approximately RMB 3 billion.

起因

In 2023, former Sogou CEO Wang Xiaochuan founded Baichuan AI; the 'Bai' (百) in the company's name means bio (biology). He said he wanted to work on healthcare from day one, but in 2023 'AI healthcare' was not a good story, so the company first positioned itself as a general-purpose model builder aiming to 'create China's OpenAI,' and in July 2024 it secured a RMB 5 billion Series A during the capital winter. In the previous decade, Wang Xiaochuan had invested in Airdoc (鹰瞳科技) and Xiaolu TCM (小鹿中医) as an individual and through Sogou, and had worked on Sogou Mingyi (搜狗明医), but none succeeded.

经过

Just half a year after the funding round, DeepSeek R1 was released, the general-purpose model story lost its scarcity, and co-founders left one after another; at the mid-year strategy meeting in July 2024, the company decided to go all in on healthcare; in April 2025, Wang Xiaochuan sent an internal memo stating that the 'front lines were stretched too far' and that the company would focus on healthcare; in March 2025, together with Beijing Children's Hospital and others, it released the Futang·Baichuan pediatric large model and proposed building an AI pediatric doctor at the attending-physician level of a Grade III Class A hospital within 3 years; on January 13, 2026, it open-sourced Baichuan-M3, which ranked first on both OpenAI's HealthBench and its Hard subset, with a medical hallucination rate of 3.5, and launched the Baixiaoying AI consultation service.

结果

Still running: as of 2026-09-01, it had about RMB 3 billion on hand and planned to launch an IPO in 2027; M3 has been open-sourced and provides consultations through Baixiaoying, and in 2026 it will release an independent consumer product focused on serious healthcare.

可借鉴之处

切换赛道时主动降低叙事调门；现金储备支撑战略定力；垂直领域的护城河是数据、信任和监管。